Key result
Switching to aliskiren did not produce significantly different blood pressure reductions compared to prior ACE inhibitor or ARB therapy in patients failing to achieve blood pressure targets.
Why the study?
Does switching to aliskiren improve blood pressure in hypertensive patients failing to achieve targets with adequate doses of ACE inhibitors or ARBs?
Observational (n=107)
No
Does switching to aliskiren improve blood pressure in hypertensive patients failing to achieve targets with adequate doses of ACE inhibitors or ARBs?
Switching to aliskiren is ineffective for further lowering blood pressure in hypertensive patients who fail to achieve targets on adequate doses of ACE inhibitors or ARBs.
Answers are grounded in this paper and cite their sources.
Does not support aliskiren switch in ACEI/ARB nonresponders; leaves open whether RCTs would alter this observational result.
BACKGROUND: To assess the efficacy of aliskiren in patients failing to reach blood pressure (BP) goals with angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). METHODS: A total of 107 patients who failed to reach BP goals on ACEI or ARB were switched to aliskiren. Changes in BP were determined during maximal ACEI, ARB, or aliskiren therapy. RESULTS: Mean reduction in sBP and dBP with ACEI was 8.5 ± 6.3 mmHg and 6.0 ± 4.7 mmHg, respectively. Mean reduction in sBP and dBP with ARB was 8.3 ± 6.7 mmHg and 5.0 ± 5.2 mmHg, respectively. Mean reduction in sBP and dBP with aliskiren 150 mg/d was 6.7 ± 5.4 mmHg and 5.4 ± 4.8 mmHg, respectively. Mean reduction in sBP and dBP with aliskiren 300 mg/d was 8.6 ± 6.3 mmHg and 6.0 ± 4.9 mmHg, respectively. BP reductions between ACEI, ARB, and aliskiren were not significantly different. CONCLUSIONS: Aliskiren is ineffective in patients failing ACEI or ARB therapy. Given the label changes restricting the use of aliskiren in combination with ACEI and ARB, excess cost compared to ACEI and ARB, and a paucity of outcome data, there is a limited role for aliskiren in practice.
No takes yet. Share an insight, caveat, or question.
E. Hawkins (2012) conducted an observational in Hypertension failing to reach blood pressure goals on ACEI or ARB (n=107). Aliskiren vs. Prior ACEI or ARB therapy was evaluated on Absolute change in systolic and diastolic blood pressure (No significant difference). Switching to aliskiren did not produce significantly different blood pressure reductions compared to prior ACE inhibitor or ARB therapy in patients failing to achieve blood pressure targets.
Synapse has enriched 10 related papers. Consider them for comparative context: